Role of TNFSF9 bidirectional signal transduction in antitumor immunotherapy

Jiao Wu; Yunpeng Wang

doi:10.1016/j.ejphar.2022.175097

Role of TNFSF9 bidirectional signal transduction in antitumor immunotherapy

Eur J Pharmacol. 2022 Aug 5:928:175097. doi: 10.1016/j.ejphar.2022.175097. Epub 2022 Jun 14.

Authors

Jiao Wu¹, Yunpeng Wang²

Affiliations

¹ Departments of Gastroenterology, Mianyang Central Hospital, Sichuan, 621000, China.
² Departments of Cardiology, Mianyang Central Hospital, Sichuan, 621000, China. Electronic address: wangyp202203@163.com.

PMID: 35714694
DOI: 10.1016/j.ejphar.2022.175097

Abstract

The complex structure of the tumor microenvironment leads to the poor efficacy of tumor immunotherapy. The therapeutic adjuvant designed to enhance the effect of T cells by acting on the costimulatory molecule tumor necrosis factor superfamily member 9 (TNFSF9) has achieved good results. However, because some tumors are characterized by reduced T-cell infiltration, adjuvants acting on T cells alone may have limitations. On the other hand, the blockade of TNFSF9 reverse signalling can have an antitumor effect by reshaping the tumor microenvironment. Therefore, this paper mainly discusses the current status and potential of TNFSF9 bidirectional signalling in antitumor immunotherapy to provide new ideas for tumor immunotherapy.

Keywords: Bidirectional signalling; TNFSF9; Tumor immunotherapy.

Publication types

Review

MeSH terms

4-1BB Ligand* / metabolism
Factor IX* / therapeutic use
Humans
Immunotherapy / methods
Neoplasms* / drug therapy
Signal Transduction*
Tumor Microenvironment

Substances

4-1BB Ligand
TNFSF9 protein, human
Factor IX